WO2006076594A3 - Antibodies and fc fusion proteins with altered immunogenicity - Google Patents

Antibodies and fc fusion proteins with altered immunogenicity Download PDF

Info

Publication number
WO2006076594A3
WO2006076594A3 PCT/US2006/001273 US2006001273W WO2006076594A3 WO 2006076594 A3 WO2006076594 A3 WO 2006076594A3 US 2006001273 W US2006001273 W US 2006001273W WO 2006076594 A3 WO2006076594 A3 WO 2006076594A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
antibodies
altered immunogenicity
immunogenicity
altered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/001273
Other languages
French (fr)
Other versions
WO2006076594A2 (en
Inventor
Gregory L Moore
Shannon Alicia Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to CA002595169A priority Critical patent/CA2595169A1/en
Priority to AU2006204791A priority patent/AU2006204791A1/en
Priority to EP06718360A priority patent/EP1858925A2/en
Publication of WO2006076594A2 publication Critical patent/WO2006076594A2/en
Publication of WO2006076594A3 publication Critical patent/WO2006076594A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Variant antibodies and Fc fusion proteins with reduced immunogenicity are described. In particular, the variants of antibodies and Fc fusion proteins have reduced ability to bind one or more human class Il MHC molecules are described.
PCT/US2006/001273 2005-01-12 2006-01-12 Antibodies and fc fusion proteins with altered immunogenicity Ceased WO2006076594A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002595169A CA2595169A1 (en) 2005-01-12 2006-01-12 Antibodies and fc fusion proteins with altered immunogenicity
AU2006204791A AU2006204791A1 (en) 2005-01-12 2006-01-12 Antibodies and Fc fusion proteins with altered immunogenicity
EP06718360A EP1858925A2 (en) 2005-01-12 2006-01-12 Antibodies and fc fusion proteins with altered immunogenicity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64331305P 2005-01-12 2005-01-12
US60/643,313 2005-01-12
US65295805P 2005-02-14 2005-02-14
US60/652,958 2005-02-14
US65463605P 2005-02-17 2005-02-17
US60/654,636 2005-02-17

Publications (2)

Publication Number Publication Date
WO2006076594A2 WO2006076594A2 (en) 2006-07-20
WO2006076594A3 true WO2006076594A3 (en) 2007-04-19

Family

ID=36678235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001273 Ceased WO2006076594A2 (en) 2005-01-12 2006-01-12 Antibodies and fc fusion proteins with altered immunogenicity

Country Status (5)

Country Link
US (1) US20060275282A1 (en)
EP (1) EP1858925A2 (en)
AU (1) AU2006204791A1 (en)
CA (1) CA2595169A1 (en)
WO (1) WO2006076594A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
KR20080073293A (en) 2005-10-14 2008-08-08 메디뮨 엘엘씨 Cell display of antibody library
EP1999470A4 (en) * 2006-03-10 2009-08-19 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
CN104761637B (en) 2006-03-31 2021-10-15 中外制药株式会社 Methods for modulating antibody hemodynamics
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2155789B1 (en) * 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
KR101680906B1 (en) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
ES2595638T3 (en) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Method to modify the isoelectric point of an antibody by replacing amino acids in a CDR
TW201634479A (en) 2007-12-05 2016-10-01 中外製藥股份有限公司 anti-NR10 antibody and its application
US20090162845A1 (en) * 2007-12-20 2009-06-25 Elazar Rabbani Affinity tag nucleic acid and protein compositions, and processes for using same
HRP20150279T1 (en) 2007-12-26 2015-05-08 Xencor, Inc. Fc variants with altered binding to fcrn
KR20160070165A (en) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Anti-ifnar1 antibodies with reduced fc ligand affinity
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
KR102057826B1 (en) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
KR20120024763A (en) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 Anti-axl antibody
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
JP5956982B2 (en) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション Method for producing antibodies having improved properties
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PT3434767T (en) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
WO2012093704A1 (en) * 2011-01-07 2012-07-12 中外製薬株式会社 Method for improving physical properties of antibody
MX352889B (en) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Fcî“riib-specific fc antibody.
AU2012258907A1 (en) * 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
US20140235475A1 (en) 2011-06-27 2014-08-21 Isabelle Carlavan Th17 differentiation markers for acne and uses thereof
CA2840405A1 (en) * 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
TWI687439B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
CN109134658B (en) 2011-10-31 2022-10-14 中外制药株式会社 Antigen binding molecules that control association of heavy and light chains
US20140302028A1 (en) * 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
PT2793943T (en) 2011-12-19 2018-11-13 Univ Rockefeller Non-sialylated anti-inflammatory polypeptides
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
JP6628966B2 (en) 2012-06-14 2020-01-15 中外製薬株式会社 Antigen binding molecule containing an altered Fc region
HK1209034A1 (en) 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
ES2876009T3 (en) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
CN105246914B (en) 2013-04-02 2021-08-27 中外制药株式会社 Fc region variants
EP3013856A2 (en) * 2013-06-27 2016-05-04 AbbVie Biotherapeutics Inc. Fc variants with improved complement activation
ES2881306T3 (en) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Method for the production of heteromultimers of polypeptides
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (en) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function.
ES2869459T3 (en) * 2014-05-16 2021-10-25 Medimmune Llc Molecules with altered neonate fc receptor binding that have enhanced therapeutic and diagnostic properties
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
JP2017529841A (en) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Chimeric antigen receptor
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
KR101860280B1 (en) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (en) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EA038554B1 (en) 2015-03-04 2021-09-14 Зе Рокфеллер Юниверсити Anti-inflammatory polypeptides
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
US10794916B2 (en) 2015-05-06 2020-10-06 Momenta Pharmaceuticals, Inc. Methods of glycoprotein analysis
WO2017086419A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Method for enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
KR102483193B1 (en) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 Non-human animals expressing an exogenous terminal deoxynucleotide transferase
HRP20260151T1 (en) * 2016-08-02 2026-03-27 Visterra, Inc. MODIFIED POLYPEPTIDES AND THEIR USE
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
US11059892B2 (en) 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
CN112119090B (en) 2018-03-15 2023-01-13 中外制药株式会社 Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
KR102259473B1 (en) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 Anti-CD137 antigen binding molecules and uses thereof
BR112021004553A2 (en) 2018-09-17 2021-06-08 Abcuro, Inc. anti-klrg1 antibodies
US20220169706A1 (en) * 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
AU2020268684C1 (en) * 2019-05-09 2026-04-02 Merus B.V. Variant domains for multimerizing proteins and separation thereof
EP4696320A2 (en) 2019-05-15 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibody
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
MX2022000111A (en) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd MOLECULES OF UNION TO CLAUDIN-6 AND THEIR USES.
EP4017542A1 (en) 2019-10-04 2022-06-29 Tae Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2022012076A (en) * 2020-05-21 2022-10-13 Zydus Lifesciences Ltd Fc variant and preparation thereof.
US20240025971A1 (en) * 2020-10-23 2024-01-25 Atreca, Inc. Antibodies to coronavirus sars-cov-2
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
EP4297796A1 (en) * 2021-02-25 2024-01-03 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
CN118119642A (en) 2021-10-28 2024-05-31 诺华股份有限公司 Engineered Fc variants
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multispecific antibodies targeting il-13 and il-18
JP2025534759A (en) * 2022-10-18 2025-10-17 クロスポイント セラピューティクス インコーポレイテッド Human antibody FC domain mutant and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066514A2 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002079232A2 (en) * 2001-03-30 2002-10-10 Merck Patent Gmbh Reducing the immunogenicity of fusion proteins
WO2004063963A2 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JP3101690B2 (en) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3051411B2 (en) * 1989-03-14 2000-06-12 持田製薬株式会社 Novel DNA and expression plasmid containing it
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5198342A (en) * 1990-07-05 1993-03-30 Immunex Corporation DNA encoding IgA Fc receptors
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5323053A (en) * 1992-05-28 1994-06-21 At&T Bell Laboratories Semiconductor devices using epitaxial silicides on (111) surfaces etched in (100) silicon substrates
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
US6365161B1 (en) * 1995-06-07 2002-04-02 Medarex, Inc. Therapeutic compounds comprised of anti-FC receptor binding agents
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0974111T3 (en) * 1997-04-11 2003-04-22 California Inst Of Techn Apparatus and method for automated protein design
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1082137A4 (en) * 1998-05-06 2004-05-19 Univ Temple INVERSION OF A PRO-INFLAMMATORY REACTION BY THE LIGATION OF THE MACROPHAGE RECEPTOR Fc $ g (g) RI
EP1105427A2 (en) * 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6306926B1 (en) * 1998-10-07 2001-10-23 3M Innovative Properties Company Radiopaque cationically polymerizable compositions comprising a radiopacifying filler, and method for polymerizing same
US6403312B1 (en) * 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US7315786B2 (en) * 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US20030049654A1 (en) * 1998-10-16 2003-03-13 Xencor Protein design automation for protein libraries
US20020048772A1 (en) * 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6649165B2 (en) * 1999-09-07 2003-11-18 Walter Schubert Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors
JP2003531588A (en) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
JP2003531149A (en) * 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ Enhancement of antibody-derived immune response
US6358733B1 (en) * 2000-05-19 2002-03-19 Apolife, Inc. Expression of heterologous multi-domain proteins in yeast
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US7235643B2 (en) * 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0118662D0 (en) * 2001-07-31 2001-09-19 Univ Southampton Binding agents
NZ571596A (en) * 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003014325A2 (en) * 2001-08-10 2003-02-20 Xencor Protein design automation for protein libraries
CA2463879C (en) * 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US6911321B2 (en) * 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
DK1534335T4 (en) * 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
HRP20170342T1 (en) * 2003-07-24 2017-05-19 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
WO2005037867A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066514A2 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002079232A2 (en) * 2001-03-30 2002-10-10 Merck Patent Gmbh Reducing the immunogenicity of fusion proteins
WO2004063963A2 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAMOW S M ET AL: "Immunoadhesins: principles and applications", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 14, no. 2, February 1996 (1996-02-01), pages 52 - 60, XP004035817, ISSN: 0167-7799 *
CHIRINO A.J., ARY M.L., MARSHALL S.A.: "Minimizing the immunogenicity of protein therapeutics", DRUG DISCOVERY TODAY, vol. 9, no. 2, 2 January 2004 (2004-01-02), pages 82 - 90, XP002395255 *
DAHIYAT B I ET AL: "Protein design automation", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 5, no. 5, May 1996 (1996-05-01), pages 895 - 903, XP002073372, ISSN: 0961-8368 *
HAYES R J ET AL: "Combining computational and experimental screening for rapid optimization of protein properties", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 25, 10 December 2002 (2002-12-10), pages 15926 - 15931, XP002340572, ISSN: 0027-8424 *
PENDLEY C ET AL: "Immunogenicity of therapeutic monoclonal antibodies", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 5, no. 2, April 2003 (2003-04-01), pages 172 - 179, XP009048367, ISSN: 1464-8431 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US12503503B2 (en) 2018-10-29 2025-12-23 Hoffmann-La Roche Inc. Bispecific anti-VEGF/ANG2 antibody formulation

Also Published As

Publication number Publication date
AU2006204791A1 (en) 2006-07-20
EP1858925A2 (en) 2007-11-28
WO2006076594A2 (en) 2006-07-20
CA2595169A1 (en) 2006-07-20
US20060275282A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2006061219A3 (en) Il-7 variants with reduced immunogenicity
WO2007056470A3 (en) Neuropilin antagonists
WO2006133088A3 (en) Improved human interferon molecules and their uses
WO2005113601A8 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
HUS1800021I1 (en) Human Anti-Il-23 Antibodies, Preparations, Procedures, and Applications
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2006082406A3 (en) Human antibodies and proteins
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
EA201490263A1 (en) CONNECTING AND MANUFACTURED WITH THEIR HELP MATERIALS
WO2005044853A3 (en) Anti-vegf antibodies
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2010065954A3 (en) Sparc binding peptides and uses thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
WO2009142460A3 (en) Antibody-peptide fused synergibody
IL178838A (en) Antibodies that bind specifically to human p-psgl-1 and p-selectin, pharmaceutical compositions comprising the antibody and nucleic acids and vectors encoding the same
WO2007079218A3 (en) Metalloproteinase binding proteins
IL177922A0 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
WO2010014922A3 (en) Protein purification tags and uses thereof
WO2006010057A3 (en) Therapeutic peptides
WO2006050341A3 (en) Modified streptococcal polysaccharides and uses thereof
WO2007007325A3 (en) Sp1 polypeptides, modified sp1 polypeptides and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2595169

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006718360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006204791

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006204791

Country of ref document: AU

Date of ref document: 20060112

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application